Jyoti D. Patel, MD, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non–small cell lung cancer.
Jyoti D. Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago Medicine, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non—small cell lung cancer.
At the 2019 ESMO Congress, a presentation on the CheckMate-227 trial showed the comparison between nivolumab (Opdivo) and ipilimumab (Yervoy) and chemotherapy alone, explains Patel. The immunotherapy combination reached statistical significance in patients with PD-L1 tumor proportion score >1%. Patients who did not have PD-L1 expression also benefited substantially from the nivolumab/ipilimumab regimen, according to Patel.
A significant number of complete responses with the combination were observed and the toxicity was well managed. These results will benefit patients who prefer a chemotherapy-free backbone, says Patel. Next, research must determine how to select patients for the immunotherapy doublet, concludes Patel.